Resources

Medical oxygen is a critical component of a well-functioning health system, yet only 30 percent of patients in low- and middle-income countries (LMICs) who need oxygen receive it. Key access barriers that drive this coverage gap include (1) supply and delivery challenges, such as limited production capacity, costly installation and maintenance requirements, and inadequate procurement and supply systems; (2) affordability, such as high cost of products and lack of local manufacturers; and (3) demand and adoption barriers, such as limited sustainable funding and limited guidelines.This fact sheet offers an overview of the INNOVATE project, which aims to address critical barriers to oxygen access. PATH, through a consortium of partners, will catalyze promising oxygen production and piping technologies, along with innovative operation and maintenance business models, to expand equitable access. By strengthening production and delivery capacity in health facilities and improving efficiency across the oxygen value chain, INNOVATE aims to accelerate the adoption of more cost-effective and sustainable solutions.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in young children. Two preventive interventions for RSV—a maternal vaccine and long-acting monoclonal antibodies (mAbs) delivered to infants—are recommended by the World Health Organization. When countries consider introducing new vaccines, immunization program cost and affordability are key questions.To address some of these questions, the University Medical Centre Utrecht and PATH conducted studies as part of a multi-country collaboration called the RSV GOLD III-Health Economics Study to evaluate the economic burden of RSV disease (or cost of illness) and the impact and cost-effectiveness of RSV prevention (e.g., via maternal immunization or long-acting monoclonal antibodies) in Gavi, the Vaccine Alliance-eligible countries. The estimates will help inform policy decisions in low- and middle-income countries where maternal immunization-preventable diseases often hit hardest.Find here links to the peer-reviewed journal articles and select fact sheets summarizing the research. [Note: Some publications and fact sheets are forthcoming.]

This document highlights the health impact of a variety of medical devices and health technologies in use around the world, such as SoloShot syringes, HEATmarker Vaccine Vial Monitors, Nifty Feeding Cups, Uniject injection systems, and safe water devices. Including innovations that have been produced at a scale of million and billions of units as well as more recent product introductions addressing critical global health needs are featured.

Urbanization in India has led to rapidly changing and diverse health needs, requiring adaptive and responsive urban health systems. However, despite initiatives such as National Urban Health Mission, dedicated health grants under Fifteenth Finance Commission, and Pradhan Mantri Ayushman Bharat Health Infrastructure Mission, persistent systemic challenges, including low community awareness of primary health services, fragmented governance across multiple departments, and weak community structures, continue to hinder comprehensive health care delivery. Existing community platforms have not sufficiently evolved to align with newer comprehensive primary health care initiatives at urban health facilities, including Urban Primary Health Centres (UPHCs) and Urban Ayushman Arogya Mandirs (UAAMs), resulting in limited uptake of services and inadequate responses to emerging public health threats. To address this gap, the National Health Mission (NHM) established Mahila Arogya Samitis (MAS) and Jan Arogya Samitis (JAS), though variably functional, offer a critical opportunity for participatory governance. This project seeks to activate and strengthen MAS and JAS in Bokaro, Jharkhand, through a systems-design approach that fosters convergence with Urban Local Bodies, establishes clear linkages and escalation pathways, and enables these community institutions to play an effective role in local health governance and community development.

Cholera remains a growing global public health threat, and the WHO-endorsed Controlled Temperature Chain (CTC) offers a practical way to improve access to oral cholera vaccines in high-risk, low-resource settings. This guidance brief describes how CTC allows eligible oral cholera vaccines to be stored and transported outside the standard 2–8°C cold chain for defined periods, reducing logistical barriers and enabling faster, more equitable delivery. Drawing on implementation experience from Bangladesh, Mozambique, and Zambia, the document outlines operational requirements, safety considerations, and key lessons learned, demonstrating that CTC can be safely applied to increase vaccination coverage, reduce costs, and support effective cholera outbreak prevention and response.